Hikma Pharmaceuticals Regulatory News (HIK)

Hikma Pharmaceuticals PLC

2023 Annual Report and Accounts and Notice of 2024 Annual General Meeting

LONDON, 22 March 2024: Hikma Pharmaceuticals PLC (the "Company") announces that, the Annual Report and Accounts for the year ended 31 December 2023 (the "Annual Report") and the Notice of the 2024 Annual General Meeting (the "Notice of AGM") are today being made available to shareholders.

The Annual Report and Notice of AGM can be viewed or downloaded from the Company's website at www.hikma.com/investors/2023-annual-report/.

In accordance with Listing Rule 9.6.1 copies of the Annual Report and Notice of AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

ENDS -

Enquiries

Hikma Pharmaceuticals PLC

Helen Middlemist +44 20 7399 2760

Group Company Secretary

22 March 2024

About Hikma

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com.

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/positive Fitch)